drugset / Trial / NCT01461109

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109 ↗

Phase 1 Completed 4 enrolled Institute for Neurodegenerative Disorders
NaSingle-groupOpen-label

Summary

The underlying goal of this study is to assess \[18F\] CFPyPB PET imaging as a tool to evaluate the activity of the GlyT1 receptors in the brain of Parkinson's Disease (PD) and Alzheimer Disease (AD) research participants.

Timeline

Start
2011-08
Primary completion
2012-09
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CFPyPB Unknown 5 ug —
Subject CFPyPB Unknown 185 mbq —